Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy

Chen, Ye; Shi, Saixian; Dai, Yan

doi:10.1016/j.biopha.2022.113903

Cited by 45 publications

(32 citation statements)

References 215 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DOX is a nonspecific cell cycle-blocking drug that inhibits DNA replication and topoisomerase activity, which breaks protein-linked double-stranded and single-stranded DNA, ultimately leading to cytotoxic DNA damage and cell death. − In addition, laser irradiation with nanomaterials having photothermal properties has a certain effect on the cell cycle arrest . We then verified whether DOX/Au-Apt@ZIF-8 nanoparticles can further improve the cell cycle blocking effect of DOX on MCF-7 cells.…”

Section: Results and Discussionmentioning

confidence: 89%

Gold-Aptamer-Modified Metal–Organic Framework Drug Delivery Nanosystems for Combined Photothermal/Chemotherapy of Cancer

Fang,

Duan,

Wan

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

The poor targeting and high toxicity of chemotherapeutic drugs make them less effective against breast cancer. In this study, in accordance with their photothermal effect, the aptamer (Apt) (AS1411) and doxorubicin (DOX) were linked to zeolite imidazole salt frame8 (ZIF-8) by using gold nanorods (Au NRs). Thereby, a multifunctional targeting nanoparticle platform (DOX/Au-Apt@ZIF-8) was constructed to deliver and effectively utilize DOX and realize the antitumor effects of the multimodal combination of chemotherapy−target−photothermal therapy. This platform was responsive to both pH and near-infrared (NIR) light.

show abstract

Section: Results and Discussionmentioning

confidence: 89%

Gold-Aptamer-Modified Metal–Organic Framework Drug Delivery Nanosystems for Combined Photothermal/Chemotherapy of Cancer

Fang,

Duan,

Wan

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…Dexrazoxane (DXZ) is currently the exclusive FDA approved drug for DOX induced cardiotoxicity treatment. However, the clinical application of DXZ is restricted because it might also protect the cancer cells against chemotherapy ( Chen et al, 2022 ). Numerous natural compounds, such as resveratrol and ginsenosides, have been tested for anti-DOX-induced cardiomyopathy in clinical trials, but few of them could genuinely achieve a clinical needs assessment ( Tatlidede et al, 2009 ; Liu et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

“…Our current findings from both in vivo and in vitro studies suggest that mitochondrial dysfunction is an essential signature of DOX-induced myocardial injury and that mesaconine may serve as a novel candidate compound targeting mitochondrial homeostasis to fight against DOX-induced cardiomyopathy, and other cardiac diseases caused by mitochondrial oxidative stress. From a clinical perspective, Aconitum carmichaelii has been widely used as a cardiotonic drug in the clinical applications of traditional Chinese medicine ( Liu et al, 2012 ; Yang et al, 2014 ; Chen et al, 2022 ). Nowdays, the Shenfu Injection is still a successful traditional Chinese medicine formulation proved with both efficacy and safety ( Tao et al, 2023 ).…”

Section: Discussionmentioning

confidence: 99%

Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy

et al. 2023

View full text Add to dashboard Cite

Aberrant mitophagy has been identified as a driver for energy metabolism disorder in most cardiac pathological processes. However, finding effective targeted agents and uncovering their precise modulatory mechanisms remain unconquered. Fuzi, the lateral roots of Aconitum carmichaelii, shows unique efficacy in reviving Yang for resuscitation, which has been widely used in clinics. As a main cardiotonic component of Fuzi, mesaconine has been proven effective in various cardiomyopathy models. Here, we aimed to define a previously unrevealed cardioprotective mechanism of mesaconine-mediated restoration of obstructive mitophagy. The functional implications of mesaconine were evaluated in doxorubicin (DOX)-induced heart failure models. DOX-treated mice showed characteristic cardiac dysfunction, ectopic myocardial energy disorder, and impaired mitophagy in cardiomyocytes, which could be remarkably reversed by mesaconine. The cardioprotective effect of mesaconine was primarily attributed to its ability to promote the restoration of mitophagy in cardiomyocytes, as evidenced by elevated expression of PINK1, a key mediator of mitophagy induction. Silencing PINK1 or deactivating mitophagy could completely abolish the protective effects of mesaconine. Together, our findings suggest that the cardioprotective effects of mesaconine appear to be dependent on the activation of PINK1-induced mitophagy and that mesaconine may constitute a promising therapeutic agent for the treatment of heart failure.

show abstract

“…Daunorubicin is an anthracycline chemotherapeutic agent that in uences diverse stages of cellular growth. However, it also induces considerable harm to normal oral mucosal tissue cells [41]. This suggests that clinical medical staff should pay more attention to monitoring blood drug concentration when administering these chemotherapy drugs.…”

Section: Disscusionmentioning

confidence: 99%

Prevalence and risk factors of chemotherapy-induced oral mucositis in 470 children with acute lymphoblastic leukemia

He,

Wang,

Liang

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: To comprehensively assess the prevalence and risk factors of chemotherapy-induced oral mucositis in 470 children diagnosed with acute lymphoblastic leukemia in China, and to gain a better understanding of the treatment-related risk factors. Methods: In this retrospective study, 470 children diagnosed with acute lymphoblastic leukemia in China between January 2020 and July 2022 were included. Data on sociodemographic characteristics, nutritional status, disease and treatment history, blood biochemistry, and microbiological factors were gathered using electronic medical records, alongside oral and dietary information collected through field investigations and telephone follow-ups. The association between chemotherapy-induced oral mucositis and these variables was assessed using univariate and multivariate logistic analyses. Results: The study found a high prevalence (45.1%) of chemotherapy-induced oral mucositis in children with acute lymphoblastic leukemia. The occurrence of oral mucositis was associated with several factors, including receiving more than five chemotherapy cycles (P<0.001), carrying HSV-1(P=0.016), being infected with Candida albicans(P=0.012), undergoing chemotherapy with specific drugs containing methotrexate/daunorubicin/cytarabine(P<0.001), having a high clinical risk stratification(P=0.002), and being over 6 years old(P=0.002). Conclusion: The study suggests that the prevalence of chemotherapy-induced oral mucositis in children with acute lymphoblastic leukemia is relatively high. It emphasizes the importance of clinical medical staff paying attention to this issue and adopting targeted interventions to reduce the prevalence of oral mucositis in this patient population.

show abstract

Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy

Cited by 45 publications

References 215 publications

Gold-Aptamer-Modified Metal–Organic Framework Drug Delivery Nanosystems for Combined Photothermal/Chemotherapy of Cancer

Gold-Aptamer-Modified Metal–Organic Framework Drug Delivery Nanosystems for Combined Photothermal/Chemotherapy of Cancer

Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy

Prevalence and risk factors of chemotherapy-induced oral mucositis in 470 children with acute lymphoblastic leukemia

Contact Info

Product

Resources

About